Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that Venn Life Sciences, a subsidiary of Open Orphan, has signed a contract renewal with a major global pharmaceutical client worth £1.5m over two years.
The renewed contract will commence in January 2022, with the Venn team in Breda providing dedicated clinical pharmacokinetics support to this leading global pharmaceutical client on an array of drug development programmes, to study the absorption, distribution, metabolism and excretion of drugs within the body.
Venn, which has been a part of Open Orphan since 2019, offers a combination of drug development consultancy, clinical trial design and execution. These combined services enable Venn to provide its clients with a complete end-to-end service on all the stages of their drug development programmes, from the early planning phase to final execution. Venn has offices in Breda (Netherlands) and Paris (France).
Cathal Friel, Executive Chairman of Open Orphan, said: “We are delighted to see this contract renewal signed by the Venn team in Breda with a client that it has been working with since 2012. The continued support by Venn to a distinguished partner such as this demonstrates the value of Venn’s clinical pharmacokinetics offering, as part of its comprehensive offering in drug development consultancy, clinical trial design and execution.
“Open Orphan’s strengths lie in the established relationships we have with our pharmaceutical partners and we expect to continue to develop these relationships as well as focusing on converting our existing pipeline of new business opportunities.”
